Acta Neuropharmacologica››2011,Vol. 1››Issue (2): 1-6.
ZHANG Ting-ting1,LIU Li-ping2,JIANG Li-ying1,HU Wei2,LONG Yan1,HONG Hao1
Online:
2011-04-26Published:
2012-04-20CLC Number:
ZHANG Ting-ting,LIU Li-ping,JIANG Li-ying,HU Wei,LONG Yan,HONG Hao. Rosiglitazone Improves Cognitive Impairment in Streptozotocin-induced Diabetic Mice and its Mechanisms[J]. Acta Neuropharmacologica, 2011, 1(2): 1-6.
[1] van den Berg E, Kessels R.P, Kappelle L.J,et al. Type 2 diabetes, cognitive function and dementia: vascularand metabolic determinants [J]. Drugs Today (Barc), 2006, 42(11):741–754. [2] Christopher T.Kodl,Elizabeth R.Seaquist. Cognitive dysfunction and diabetes mellitus[J]. Endocr Rev, 2008, 29(4):494 -511. [3] Rodney A.Velliquette , Tracy O’ Connor, Robert Vassar. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer’s disease pathogenesis[J]. J Neurosci,2005, 25(47): 10874-10883. [4] Kamal A, Biessels GJ, Gispen WH,et al. Synaptic transmission changes in the pyramidal cells of the hippocampus in streptozotocin-induced diabetes mellitus in rats [J]. Brain Res, 2006, 1073-1074:276-280. [5] Liu Liping, Hong Hao, Liao Jianming,et al. Upregulation of RAGE at the blood-brain barrier in streptozotocin-induced diabetic mice [J]. Synapse, 2009, 63(8):636-642. [6] Watson G.Stennis, Cholerton Brenna A, Reger Mark A,et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study [J]. Am J Geriatr Psychiatry, 2005,13(11):950-958. [7] Risner ME, Saunders AM, Altman JF,et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease [J]. Pharmacogenomics J,2006,6(4):246-254. [8] Brands AM, Kessels RP, de Haan EH,et al. Cerebral dysfunction in type1 diabetes: effects of insulin, vascular risk factors and blood glucose levels [J]. Eur J Pharm acol,2004,490(123):159-168. [9] Alexis M Stranahan, Thiruma V Arumguam, Roy G Cutler,et al. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons [J]. Nat Neurosci, 2008,11(3):309-317. [10] Huang Weichan, Shiow-Wen Juang, I.Min Liu,et al. Changes of superoxide dismutase gene expression and activity in the brain of streptozotocin-induced diabetic rats [J]. Neurosci Lett,1999,275(1):25-28. [11] 曲忠森, 赵永波, 刘文文,等. 胰岛素降低糖尿病大鼠大脑皮层β淀粉样蛋白含量的可能机制[J].中华神经科杂志,2006,39(6):392-395. [12] Han Weiping, Cai Li. Linking type 2 diabetes and Alzheimer's disease [J]. Proc Natl Acad Sci USA,2010,107(15):6557-6558. [13] Sakurai T. Targets of the peroxisome proliferator-activated receptor γ agonist trials for the prevention of Alzheimer disease [J]. Arch Neurol,2011, 68(1):542-543. [14] Ward A Pedersen, Pamela J.McMillan, J.Jacob Kulstad,et al. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice [J].Exp Neurol,2006,199(2):265-273. [15] Asif R. Pathan, Anil Bhanudas Gaikwad, Bhoomi Viswanad,et al. Rosiglitazone attenuates the cognitive deficits induced by high fat diet feeding in rats [J]. European J Pharmacol, 2008, 589(1-3):176–179. |
[1] | LIU Shan, LI Wei.Research Progress on Pharmacological Effects of L-theanine[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(2): 24-32. |
[2] | ZHENG Bei-bei, FENG Shuo, GUO Meng-yuan, FENG Pu, CEN Juan, ZHANG Feng.The Role of Reactive Oxygen Species in Promoting Angiogenesis and Its Important Role in Intracerebral Diseases[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(1): 24-28. |
[3] | ZHANG Qun-feng,HE Huan-ying,LIAO Yun-hao,WANG Guo-qing.The Effects of Maternal Chlorpyrifos Exposure on the Expression of COX2,CREB and BDNF in Hippocampus of Offspring Mice[J]. Acta Neuropharmacologica, 2019, 9(6): 1-5. |
[4] | QI Gi,WU Hong-li,QI Quan, et al.Correlation between Progesterone Supplementation in the Early Pregnancy and Incidence of Gestational Diabetes Mellitus[J]. Acta Neuropharmacologica, 2019, 9(6): 6-10. |
[5] | YANG Jing,YUAN Wen-ying.Toxoplasma Infection on Nerve Tissue Damage and Its Mechanism through the Blood-Brain Barrier[J]. Acta Neuropharmacologica, 2019, 9(5): 40-43. |
[6] | ZHANG Shuai,AI Jing.Glutamate Dysfunction and Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2018, 8(6): 9-20. |
[7] | SUN Yan-yun,WANG Meng-wei,JIN Xin-chu.Chronic Nicotine Treatment Alleviates Schizophrenia-Induced Memory Deficit through Regulating Pdlim5 and CRTC1 in Mice[J]. Acta Neuropharmacologica, 2018, 8(4): 6-7. |
[8] | ZHANG Fang-fang1,ZHOU Yan-memg1,WANG Hao1,GAO Shan1,WANG Lei1,TAN Rui1,DU Xian1,ZHAO Xiao-min1,ZHANG Han-ting1,2 *.PDE4 Inhibitor Ameliorates Neuropathic Pain by Upregulating Spinal Connexin 43 Expression[J]. Acta Neuropharmacologica, 2018, 8(4): 8-9. |
[9] | LIU Cai-hong,WU Xian,TANG Su-su,HONG Hao*.Involvement of TGR5 in Aβ-Induced Neurotoxicity in Vivo[J]. Acta Neuropharmacologica, 2018, 8(4): 11-12. |
[10] | WANG Hao1, ZHANG Fang-fang1, FU Hua-rong1, ZHOU Yan-meng1, LIU Xin1, HOU Xue-qin 1, HU Wei2, Rolf Hansen2, XU Ying3, James O’Donnell3, ZHANG Han-ting1,2.Targeting PDE4 for Alzheimer’s Disease and Alcoholism: An implication in Alcohol-Related Dementia?[J]. Acta Neuropharmacologica, 2018, 8(4): 39-41. |
[11] | WU Xian, LV Yang-ge, TANG Su-Su, HONG Hao.Involvement of TGR5 in Aβ-induced Neurotoxicity in Vivo[J]. Acta Neuropharmacologica, 2018, 8(4): 53-54. |
[12] | SUN Yi,TAN Bo,SU Rui-bin.Biased Ligand——Novel Paradigm for Opioid Analgesics[J]. Acta Neuropharmacologica, 2018, 8(2): 1-7. |
[13] | LIN Zhi-bin.Pharmacological Progress of Ganoderma on Anti-aging and Anti-Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2018, 8(1): 9-15. |
[14] | ZAN Gui-ying,SUN Xiang,LI Qing-lin,LIU Jing-gen.Research Progress of the Role and Underlying Mechanism of Dynorphin/κ Opioid Receptor in the Development of Depression[J]. Acta Neuropharmacologica, 2018, 8(1): 54-64. |
[15] | BAI Yan-chang,JIA Yan-li,WANG Jian-hua.Value of Neuroimaging in Vascular Cognitive Impairment[J]. Acta Neuropharmacologica, 2017, 7(6): 1-6. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||